Clinical Trial Update: Lenvatinib in Second Line Endometrial Carcinoma [Phase 2]

View source ↗

Summary

The Phase 2 clinical trial of lenvatinib for second-line endometrial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Endometrial Neoplasms | Phase 2 | Status: WITHDRAWN